![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PPARGC1A |
Gene summary for PPARGC1A |
![]() |
Gene information | Species | Human | Gene symbol | PPARGC1A | Gene ID | 10891 |
Gene name | PPARG coactivator 1 alpha | |
Gene Alias | LEM6 | |
Cytomap | 4p15.2 | |
Gene Type | protein-coding | GO ID | GO:0000002 | UniProtAcc | Q9UBK2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10891 | PPARGC1A | HTA11_3410_2000001011 | Human | Colorectum | AD | 8.31e-19 | -6.52e-01 | 0.0155 |
10891 | PPARGC1A | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.04e-02 | -4.65e-01 | -0.1207 |
10891 | PPARGC1A | HTA11_866_3004761011 | Human | Colorectum | AD | 2.46e-13 | -5.83e-01 | 0.096 |
10891 | PPARGC1A | HTA11_9408_2000001011 | Human | Colorectum | AD | 5.05e-04 | -8.05e-01 | 0.0451 |
10891 | PPARGC1A | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.25e-04 | -7.11e-01 | 0.0528 |
10891 | PPARGC1A | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.06e-10 | -6.81e-01 | 0.0338 |
10891 | PPARGC1A | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.89e-19 | -5.75e-01 | 0.0674 |
10891 | PPARGC1A | HTA11_6818_2000001011 | Human | Colorectum | AD | 6.01e-03 | -6.23e-01 | 0.0112 |
10891 | PPARGC1A | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.35e-04 | -4.07e-01 | 0.294 |
10891 | PPARGC1A | HTA11_99999965104_69814 | Human | Colorectum | MSS | 6.52e-03 | -4.76e-01 | 0.281 |
10891 | PPARGC1A | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.91e-14 | -5.37e-01 | 0.3859 |
10891 | PPARGC1A | HTA11_99999973899_84307 | Human | Colorectum | MSS | 8.07e-08 | -6.95e-01 | 0.2585 |
10891 | PPARGC1A | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.63e-37 | -7.87e-01 | 0.3005 |
10891 | PPARGC1A | F007 | Human | Colorectum | FAP | 2.81e-05 | -3.94e-01 | 0.1176 |
10891 | PPARGC1A | A001-C-207 | Human | Colorectum | FAP | 3.90e-09 | -4.80e-01 | 0.1278 |
10891 | PPARGC1A | A015-C-203 | Human | Colorectum | FAP | 1.22e-28 | -6.23e-01 | -0.1294 |
10891 | PPARGC1A | A015-C-204 | Human | Colorectum | FAP | 1.29e-08 | -4.66e-01 | -0.0228 |
10891 | PPARGC1A | A014-C-040 | Human | Colorectum | FAP | 1.91e-05 | -5.20e-01 | -0.1184 |
10891 | PPARGC1A | A002-C-201 | Human | Colorectum | FAP | 3.93e-17 | -4.95e-01 | 0.0324 |
10891 | PPARGC1A | A002-C-203 | Human | Colorectum | FAP | 1.06e-07 | -4.13e-01 | 0.2786 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004218021 | Liver | HCC | cellular ketone metabolic process | 123/7958 | 211/18723 | 2.52e-06 | 3.37e-05 | 123 |
GO:003025821 | Liver | HCC | lipid modification | 123/7958 | 212/18723 | 3.50e-06 | 4.58e-05 | 123 |
GO:000914212 | Liver | HCC | nucleoside triphosphate biosynthetic process | 57/7958 | 85/18723 | 4.10e-06 | 5.27e-05 | 57 |
GO:000756822 | Liver | HCC | aging | 185/7958 | 339/18723 | 4.28e-06 | 5.50e-05 | 185 |
GO:000915212 | Liver | HCC | purine ribonucleotide biosynthetic process | 101/7958 | 169/18723 | 4.30e-06 | 5.50e-05 | 101 |
GO:00192162 | Liver | HCC | regulation of lipid metabolic process | 181/7958 | 331/18723 | 4.58e-06 | 5.79e-05 | 181 |
GO:000974622 | Liver | HCC | response to hexose | 126/7958 | 219/18723 | 4.81e-06 | 6.06e-05 | 126 |
GO:007054221 | Liver | HCC | response to fatty acid | 45/7958 | 64/18723 | 6.18e-06 | 7.56e-05 | 45 |
GO:00063671 | Liver | HCC | transcription initiation from RNA polymerase II promoter | 52/7958 | 77/18723 | 7.87e-06 | 9.27e-05 | 52 |
GO:0048285 | Liver | HCC | organelle fission | 254/7958 | 488/18723 | 1.07e-05 | 1.23e-04 | 254 |
GO:001082312 | Liver | HCC | negative regulation of mitochondrion organization | 36/7958 | 49/18723 | 1.08e-05 | 1.24e-04 | 36 |
GO:00106752 | Liver | HCC | regulation of cellular carbohydrate metabolic process | 88/7958 | 146/18723 | 1.08e-05 | 1.24e-04 | 88 |
GO:000974912 | Liver | HCC | response to glucose | 121/7958 | 212/18723 | 1.24e-05 | 1.39e-04 | 121 |
GO:00091995 | Liver | HCC | ribonucleoside triphosphate metabolic process | 58/7958 | 89/18723 | 1.31e-05 | 1.45e-04 | 58 |
GO:000914412 | Liver | HCC | purine nucleoside triphosphate metabolic process | 57/7958 | 88/18723 | 2.03e-05 | 2.17e-04 | 57 |
GO:007139821 | Liver | HCC | cellular response to fatty acid | 29/7958 | 38/18723 | 2.35e-05 | 2.47e-04 | 29 |
GO:007252212 | Liver | HCC | purine-containing compound biosynthetic process | 114/7958 | 200/18723 | 2.36e-05 | 2.49e-04 | 114 |
GO:007155921 | Liver | HCC | response to transforming growth factor beta | 141/7958 | 256/18723 | 3.08e-05 | 3.16e-04 | 141 |
GO:00092015 | Liver | HCC | ribonucleoside triphosphate biosynthetic process | 49/7958 | 74/18723 | 3.21e-05 | 3.26e-04 | 49 |
GO:004347021 | Liver | HCC | regulation of carbohydrate catabolic process | 39/7958 | 56/18723 | 3.63e-05 | 3.61e-04 | 39 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05016 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
hsa04714 | Colorectum | AD | Thermogenesis | 120/2092 | 232/8465 | 2.76e-19 | 1.16e-17 | 7.37e-18 | 120 |
hsa04152 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
hsa04922 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa04211 | Colorectum | AD | Longevity regulating pathway | 33/2092 | 89/8465 | 6.15e-03 | 2.68e-02 | 1.71e-02 | 33 |
hsa050161 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
hsa047141 | Colorectum | AD | Thermogenesis | 120/2092 | 232/8465 | 2.76e-19 | 1.16e-17 | 7.37e-18 | 120 |
hsa041521 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
hsa049221 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa042111 | Colorectum | AD | Longevity regulating pathway | 33/2092 | 89/8465 | 6.15e-03 | 2.68e-02 | 1.71e-02 | 33 |
hsa047142 | Colorectum | SER | Thermogenesis | 106/1580 | 232/8465 | 1.15e-21 | 6.34e-20 | 4.61e-20 | 106 |
hsa050162 | Colorectum | SER | Huntington disease | 127/1580 | 306/8465 | 3.29e-21 | 1.37e-19 | 9.92e-20 | 127 |
hsa049222 | Colorectum | SER | Glucagon signaling pathway | 38/1580 | 107/8465 | 2.57e-05 | 3.28e-04 | 2.38e-04 | 38 |
hsa047143 | Colorectum | SER | Thermogenesis | 106/1580 | 232/8465 | 1.15e-21 | 6.34e-20 | 4.61e-20 | 106 |
hsa050163 | Colorectum | SER | Huntington disease | 127/1580 | 306/8465 | 3.29e-21 | 1.37e-19 | 9.92e-20 | 127 |
hsa049223 | Colorectum | SER | Glucagon signaling pathway | 38/1580 | 107/8465 | 2.57e-05 | 3.28e-04 | 2.38e-04 | 38 |
hsa050164 | Colorectum | MSS | Huntington disease | 141/1875 | 306/8465 | 2.90e-21 | 1.62e-19 | 9.92e-20 | 141 |
hsa047144 | Colorectum | MSS | Thermogenesis | 113/1875 | 232/8465 | 1.52e-19 | 4.62e-18 | 2.83e-18 | 113 |
hsa049224 | Colorectum | MSS | Glucagon signaling pathway | 39/1875 | 107/8465 | 5.00e-04 | 3.45e-03 | 2.11e-03 | 39 |
hsa042112 | Colorectum | MSS | Longevity regulating pathway | 33/1875 | 89/8465 | 9.33e-04 | 5.58e-03 | 3.42e-03 | 33 |
Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
PPARGC1A | ICAF | Cervix | HSIL_HPV | SEMA3B,SLC7A2,KIAA0408, etc. | 2.52e-02 | ![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPARGC1A | SNV | Missense_Mutation | rs749421285 | c.1063T>A | p.Tyr355Asn | p.Y355N | Q9UBK2 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
PPARGC1A | SNV | Missense_Mutation | rs139240743 | c.1841G>A | p.Arg614Gln | p.R614Q | Q9UBK2 | protein_coding | tolerated(0.06) | benign(0.018) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPARGC1A | SNV | Missense_Mutation | c.695N>T | p.Ser232Ile | p.S232I | Q9UBK2 | protein_coding | deleterious(0.03) | possibly_damaging(0.491) | TCGA-B6-A0RL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PPARGC1A | SNV | Missense_Mutation | novel | c.202N>A | p.Gln68Lys | p.Q68K | Q9UBK2 | protein_coding | deleterious(0) | benign(0.22) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPARGC1A | SNV | Missense_Mutation | c.1817G>A | p.Ser606Asn | p.S606N | Q9UBK2 | protein_coding | tolerated_low_confidence(0.26) | benign(0.007) | TCGA-BH-A0E1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
PPARGC1A | SNV | Missense_Mutation | c.1978N>C | p.Glu660Gln | p.E660Q | Q9UBK2 | protein_coding | tolerated(0.08) | benign(0.153) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
PPARGC1A | SNV | Missense_Mutation | novel | c.1511G>A | p.Gly504Glu | p.G504E | Q9UBK2 | protein_coding | tolerated_low_confidence(0.11) | probably_damaging(0.999) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PPARGC1A | SNV | Missense_Mutation | novel | c.2271N>A | p.Phe757Leu | p.F757L | Q9UBK2 | protein_coding | tolerated(0.26) | benign(0.001) | TCGA-C5-A901-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PPARGC1A | SNV | Missense_Mutation | c.664N>T | p.His222Tyr | p.H222Y | Q9UBK2 | protein_coding | deleterious(0.02) | benign(0.388) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
PPARGC1A | SNV | Missense_Mutation | rs143103266 | c.1951N>T | p.Arg651Cys | p.R651C | Q9UBK2 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |